Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2000

View Archived Issues

Case studies reveal that gabapentin reduces the frequency of hot flashes

Pilot trial of IL-10 demonstrates improvement in liver histology in chronic HCV patients

(S)-Oxybutynin phase II trial successfully completed

FDA approves Apligraf for diabetic foot ulcers

Celgene and NCI to enter into cooperative R&D agreement for IMiDs

Novavax to begin phase I trial of Androsorb testosterone replacement therapy for women

Corvas completes enrollment for rNAPc2 phase II study

Extended-release venlafaxine proven safe and effective for the treatment of GAD

Applied Molecular Evolution creates anti-RSV monoclonal antibodies

Antibacterial efficacy results of Demegen peptide compound presented

Collaboration to develop CpG DNA-based cancer products

AVI BioPharma and DepoMed explore oral delivery of AVI's antisense agents

Taiwan researchers patent AT1 receptor antagonists with potential in cardiovascular conditions

PNU-190192 and related indolylpyrrolidinemethylpyrrole derivatives as immunosuppressants

Potent tricyclic protein farnesyltransferase inhibitors described by Schering-Plough

Structurally novel compounds synthesized at Leo exert potent insulinotropic activity

Peptide inhibitors of procollagen C-proteinase useful for fibrotic disorders

Agents for herpesvirus infections in development at Boehringer Ingelheim

Novel neuroprotective compounds exert NMDA-activating, AMPA-inhibiting effects

New phospholipase A2 inhibitors presented by Elan in patent literature

Triangle updates development status of clevudine

Japanese team designs new type of anti-HIV prodrug comprising a protease inhibitor and RT inhibitor

LM-1507.Na -- a potent and selective Cys-LT1 receptor antagonist with oral activity

Liposomal formulation of PGE1 prodrug shows promise in peripheral arterial occlusive disease

Nature article reports new anti-TB compound with unique properties

Marimastat does not meet primary or secondary endpoints in brain cancer trial

First clinical results reported for TS-943, a new small-molecule antiplatelet agent

Additive or synergistic effects of surfactant and PDE4 inhibitor in acute lung injury